Latest on Pharmaceutical Industry


Pfizer's Xeljanz gets FDA nod as joint disease treatment

U.S. drugmaker Pfizer Inc said on Thursday the U.S. Food and Drug Administration (FDA) approved two doses of its drug Xeljanz for treatment of a joint disease. Xeljanz was approved as a 5-mg dose taken twice daily and..Read More...

Merck's Keytruda fails pivotal gastric cancer trial

Merck & Co Inc said on Thursday a key late-stage trial testing its blockbuster drug, Keytruda, failed to meet its main goal of extending lives of patients with a type of gastric cancer. The trial, which was testing th..Read More...



Nepal Lab – The Lab Expo 2017

Bhrikuti Mandap Exhibition Hall,
Nepal ,
S.D. Promo Media Pvt. Ltd.


10th Annual Conference Biotech Showcase 2018

EBD Group

Press Releases

Cerveau Technologies, Inc. Signs Research Agreement with KU Leuven University, Belgium

Cerveau Technologies Inc today announced an agreement with the KU Leuven university in Belgium to support multiple projects over the next several years These research projects are for studies of an early stage imaging ag.. Read More...

Arrakis Therapeutics Announces Exclusive License to RNA-targeted Small Molecule Technology from the University of Pennsylvania

Arrakis Therapeutics a pioneering biopharmaceutical company announced that it has entered into an exclusive license agreement with the University of Pennsylvania to access intellectual property and technology related to .. Read More...

Suppliers of the Month

Product Launch



Latest Reports


Latest Projects


Expert Talk

Bayer Pharmaceuticals

Bayer Pharmaceuticals Christoph Huwe PhD CAAM is a Strategic Alliance Manager Therapeutics at Bayer AG Pharmaceuticals with a focus on the BayerEvotec Endometriosis BayerEvotec Kidney Diseases BayerOncoMed Oncology strategic alliances and the Tuberculosis Drug Accelerator consortium He is also a member of Bayers Alliance. Read More...
Christoph Huwe
Strategic Alliance Manager Therapeutics